Advertisement

Topics

RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%

08:06 EDT 28 Jul 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Consolidated revenues € 587.9 million, +9.1%. EBITDA(1) € 188.1 million, +14.8% Operating income € 170.2 million, +17.2%. Net income € 122.7 million, +18.9%. Net financial position(2):  net debt of € 164.4 million. Sharehol...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "RECORDATI: EXCELLENT RESULTS IN THE FIRST HALF 2016. CONTINUED GROWTH IN SALES +9.1%, OPERATING INCOME +17.2%, NET INCOME +18.9%"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...